Exelixis says 505(b)(2) cabozantinib rivals such as Handa’s Omcazio pose limited commercial risk to Cabometyx, while the originator continues to plan around conventional generic entry from 2031.
Exelixis says 505(b)(2) cabozantinib rivals such as Handa’s Omcazio pose limited commercial risk to Cabometyx, while the originator continues to plan around conventional generic entry from 2031.